Compass Pathways PLC (NASDAQ:CMPS) is among the best psychedelic stocks to buy in 2026. Its flagship psychedelic drug ...
COMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically ...
Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss. Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year.
Compass Pathways (NASDAQ:CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch ...
1mon
Analysts Bullish on COMPASS Pathways plc (CMPS) Following Psychedelics Symposium and Model Updates
COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...
LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful ...
Compass Pathways (NASDAQ: CMPS) is not your typical healthcare company. The London-based clinical-stage biopharma is developing therapies for various forms of depression that center around psilocybin, ...
This article was originally published on PSYCH and appears here with permission. UK-based COMPASS Pathways (NASDAQ:CMPS) recently published data from its Phase IIb trials, with COMP360 psilocybin ...
LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results